PHILADELPHIA and WALTHAM, Mass., Nov. 4, 2015 – Spark Therapeutics announced today that it has
expanded into the greater Boston area, where the company has opened a new satellite office. With Spark’s
corporate and research headquarters remaining in west Philadelphia, the company has opened an office
at 1000 Winter Street in Waltham, to support the growth of several departments, including the commercial,
medical, patient advocacy and business development groups.
“Over the past year, Spark has doubled in size, and we are continuing to expand to meet the needs of our
growing business,” said Jeffrey D. Marrazzo, co-founder and chief executive officer of Spark. “With
successful completion of the Phase 3 pivotal trial of our lead gene therapy product candidate last month,
we are building out teams in both offices to support commercialization activities and the future expansion
of our growing pipeline. Our presence in the greater Boston area puts Spark in a prime position to readily
access top talent in both burgeoning biotech hubs.”
There are currently job openings in Spark’s quality assurance, regulatory affairs, technical operations and
commercial groups. Visit the “Careers” section of Spark’s website at www.sparktx.com for more information.
About Spark Therapeutics
Spark is a gene therapy leader seeking to transform the lives of patients with debilitating genetic diseases
by developing one-time, life-altering treatments. Spark’s initial focus is on treating rare diseases where no,
or only palliative, therapies exist. Spark’s most advanced product candidate, SPK-RPE65, which has
received both breakthrough therapy and orphan product designation, recently reported positive top-line
results from a pivotal Phase 3 clinical trial for the treatment of rare blinding conditions. Spark’s validated
gene therapy platform is being applied to a range of clinical and preclinical programs addressing serious
genetic diseases, including inherited retinal dystrophies, hematologic disorders and neurodegenerative
diseases. Spark builds on two decades of research, development and manufacturing at The Children’s
Hospital of Philadelphia, including human trials conducted across diverse therapeutic areas and routes of
administration. To learn more, please visit www.sparktx.com.
Cautionary Note on Forward-looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, including statements regarding the company’s lead product candidate, SPK-RPE65.
Any forward-looking statements are based on management’s current expectations of future events and are
subject to a number of risks and uncertainties that could cause actual results to differ materially and
adversely from those set forth in, or implied by, such forward-looking statements. These risks and
uncertainties include, but are not limited to, the risk that: (i) the data from our Phase 3 clinical trial of SPKRPE65 may not support a label for the treatment of RPE65-mediated IRDs other than Leber congenital
amaurosis (LCA); (ii) the improvements in functional vision demonstrated by SPK- RPE65 in our clinical
trials may not be sustained over extended periods of time; and (iii) we could experience delays in submitting
our regulatory filings, including our Biologics Licensing Application with FDA and, once submitted, such
regulatory filings may not be approved; (iv) our product candidate, SPK-CHM, will not demonstrate sufficient
clinical data to warrant continued development; (v) our collaboration with Pfizer will not be successful; and
(vi) any one or more of our product candidates in preclinical or clinical development will not successfully be
developed and commercialized. For a discussion of other risks and uncertainties, and other important
factors, any of which could cause our actual results to differ from those contained in the forward-looking
statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other
important factors, in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and other filings
we make with the Securities and Exchange Commission. All information in the press release is as of the
date of the release, and Spark undertakes no duty to update this information unless required by law.
Contacts
Investor Relations
Spark Therapeutics, Inc.
Stephen W. Webster
Chief Financial Officer
(855) SPARKTX (1-855-772-7589)
Media
Ten Bridge Communications
Dan Quinn
(781) 475-7974
dan@tenbridgecommunications.com
Financial Media
Teneo Strategy
Andy Maas
(212) 886-9321
andy.maas@teneostrategy.com
